WCCC summit spotlights new wound care evidence and regulatory shifts

By AI, Created 1:55 PM UTC, May 19, 2026, /AGP/ – The 2026 Wound Care Collaborative Community summit in Charlotte highlighted new FDA and CMS-aligned evidence efforts, including longitudinal data projects and patient-centered initiatives. Organizers said the changes could shape trial design, coverage decisions and access to wound care products.

Why it matters: - Wound care products are facing tighter expectations for clinical evidence, regulatory alignment and coverage support. - The summit framed these changes as a direct factor in how quickly new therapies reach patients. - WCCC is positioning itself as a pre-competitive forum where industry, regulators and clinicians can help shape the standards.

What happened: - HMP Global hosted the 2026 Wound Care Collaborative Community Driving Innovation in Wound Care Summit alongside the annual Symposium on Advanced Wound Care Spring in Charlotte, North Carolina. - The event highlighted clinical, regulatory and industry developments that are expected to affect wound care evaluation and adoption. - The summit featured 36 faculty members from industry, FDA CDER and CDRH, clinical practice and research. - The program was moderated by Robyn Bent, Yu-Chieh Chiu, Vickie R. Driver and Rachana K. Visaria. - Driver said, “Where does innovation happen? Right here. Innovation starts here. It starts with you. It starts with me. In fact, it goes on with us. So, let’s bring it forward.”

The details: - CMS reform and evolving FDA pathways are increasing the value of high-quality clinical evidence in wound care. - The Natural History Project is under peer review, and its findings are expected to affect trial design, endpoint selection and coverage policy. - Project STEADY is set to launch in summer 2026 with access to 10 years of longitudinal real-world diabetic foot data. - The FDA TAP program is expanding to wound care, giving sponsors a way to better align FDA, CMS and payer expectations earlier in development. - The FDA-led Voice of the Patient initiative is planned for August 2026 and is intended to help define patient-centered endpoints for future regulatory submissions. - WCCC described the collaborative model as a way to define evidence expectations across the wound care sector.

Between the lines: - The summit signals that wound care innovation is moving closer to a data-first model, where reimbursement and regulatory strategy are becoming as important as product performance. - The emphasis on pre-competitive collaboration suggests companies may need to engage earlier with shared evidence frameworks instead of treating FDA and payer requirements separately. - The mix of FDA, clinicians and industry participants points to a more coordinated effort to standardize how wound care evidence is generated and judged.

What’s next: - WCCC said stakeholders can visit the refreshed website to follow the Natural History Project and Project STEADY and join ongoing collaborative efforts. - The organization is also encouraging participation through its volunteer program to support evidence development and regulatory alignment. - Project STEADY, the Voice of the Patient initiative and the expanded TAP pathway are the main near-term milestones named by the summit. - HMP Global said the refreshed digital platform is part of its broader effort to support ongoing engagement in wound care.